Navigation Links
Dallas-Fort Worth Fertility Associates Celebrates First Birth in North Texas from Advanced Trophectoderm Biopsy Screening Technology
Date:12/18/2012

Dallas, Texas (PRWEB) December 18, 2012

Dallas-Fort Worth Fertility Associates announces one of North Texas’ first live births with blastocyst embryo biopsy, an emerging technology used to screen embryos for chromosomal abnormalities before embryo transfer in an in vitro fertilization cycle.

This method uses an advanced laser system to create an opening in the outer shell of an embryo, then to remove cells from the “trophectoderm,” the outer part of a blastocyst (5-day old embryo) that ultimately develops into the placenta. A trophectoderm biopsy of the blastocyst significantly improves the chances for conception for parents experiencing infertility compared to other embryo biopsy technologies.

“The success of this pregnancy signifies the viability of trophectoderm biopsy as another resource to help couples achieve their parenthood dreams,” explained Dr. Sam Chantilis, medical director of Dallas-Fort Worth Fertility Associates.

To view video of Trophectoderm Biopsy, Click Here

In the current case, Dr. Chantillis was working with a couple that had specific concerns about a sex-linked genetic abnormality. Dallas-Fort Worth Fertility Associates utilized the trophectoderm biopsy to look for healthy female embryos before performing the transfer.

“It was important that this patient and her husband not have to worry about passing on any genetic disorders to their children,” said Dr. Chantilis.

With the trophectoderm biopsy, embryologists can perform a thorough genetic analysis of multiple cells on five-day-old embryos. In the past, technicians could only assess the genetic material of one cell from an embryo on the third day after IVF egg retrieval.

“Before this, preimplantation genetic screening (PGS) was performed in the fertility lab using the genetic material from one cell of an eight-cell embryo,” Dr. Chantillis said. “The limited amount of available genetic material in the eight-cell embryo and genetic variability of the various cells in a three-day old embryo made the analysis less accurate.”

Dr. Chantillis explains that the trophectoderm biopsy enables embryologists to remove the cells when the embryos are five and six days old and has developed 60 to 80 cells. This allows fertility specialists to screen the X and Y chromosomes, as well as 22 autosomal chromosomes.

The new PGS protocol evaluates the embryos on Day 5, so the final transfer is delayed at least one month. Once the best embryos are identified, they are preserved using an innovative fast-freezing process called vitrification. The improved method of preserving embryos results in less damage during freezing and thawing.

“This technology is the wave of the future for reproductive medicine,” Dr. Chantilis said. “We are thrilled to have another tool in our arsenal that allows us to help those struggling with infertility create their families.”

About Dallas Fertility Associates
Dallas-Fort Worth Fertility Associates is a private practice physicians' office specializing in reproductive endocrinology and infertility treatment. Dr. Samuel J. Chantilis, Dr. Karen L. Lee, Dr. Mika R. Thomas and Dr. Ravi Gada, our fertility specialists, are all fellowship-trained in reproductive endocrinology and infertility. Our clinic was opened in an effort to bring the latest IVF treatments and procedures to the Dallas-Fort Worth community. For more information, please visit http://www.dallasfertility.com.

Read the full story at http://www.prweb.com/releases/DFA/2012/prweb10229756.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Global Membrane Bioreactor (MBR) Systems Market Worth $2,052 Million by 2017
2. Global Biobank Market Worth $3.9 Billion by 2017
3. Global Medical Image Analysis Software Market Worth $2.4 Billion by 2017
4. MarketsandMarkets: Global Refurbished Medical Equipments Market worth $8.45 Billion by 2017
5. MarketsandMarkets: Global Spine Surgery Devices Market Worth $14.8 Billion by 2017
6. The Law Office of Roger G. Worthington, P.C. - Longtime Supporter of the Pacific Meso Center - Donates $100,000 for Mesothelioma Research
7. MarketsandMarkets: Global Next Generation Biometric Technologies Market worth $13.89 Billion by 2017
8. Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets
9. Professor Doel Soejarto to Receive ABCs Farnsworth Excellence in Botanical Research Award
10. MarketsandMarkets: Global Biomarkers Market worth $25.79 Billion by 2016
11. MarketsandMarkets: Global Clinical Trial Management Systems Market Worth $1300.4 Million by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... OR (PRWEB) , ... January 18, 2017 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 ... Cyclone V E FPGA into a compact business-card sized form factor suitable for ...
(Date:1/18/2017)... Jan. 18, 2017 Applied BioMath ( ... to drug research and development, today announced that ... and CEO of Applied BioMath, will present at ... Modeling (BAGIM) Meeting on Thursday January 19, 2017 ... , MA.   Dr. Burke,s talk "Quantitative Modeling ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total ... successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, ... The procedure was an anterior cervical discectomy and fusion on a 42 year ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, ... that it has submitted a 510(k) to the FDA, requesting clearance of the ... functional electrical stimulation (FES) technology. , The submission marks a major milestone ...
Breaking Biology Technology:
(Date:12/20/2016)... LONDON , Dec. 20, 2016 ... car sharing, rental and leasing is stoking significant ... of radio frequency technology, Bluetooth low energy (BLE), ... emerge as the next wave of wireless technologies ... vehicle access system to advanced access systems opens ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
Breaking Biology News(10 mins):